INBX Inhibrx Inc

$INBX For those who are interested: Block the fudsters. It is down because of GMAB/MRUS data. Yes, it will be tough now for their lead program 106. There is a chance though for a 20% number of patients. Program 109 is still very compelling and promising and will probably be approved next April. .5b to 1b peak sale potential for 109 in my opinion. ATM not needed at this stage. No position, just explaining.

$INBX summary of Stifel’s Anayst note this morning which nails it. INBX is going to win HPV+ which is a $4B market. Plus 109 and plus coming lung data. Stupid cheap here. Stifel’s new note argues the $INBX selloff gives too much weight to Genmab’s overall results and too little to 106’s potential differentiation in HPV+. Their modeling suggests Genmab’s overall ORR could be approximately 43–53%, below its earlier 63%, although actual response rates remain undisclosed. The strongest bullish point: 106’s early response depth, complete responses and durability could support preferred first-line use in HPV+ if replicated. Genmab’s impressive overall survival result does not settle that subgroup competition. Stifel also highlights overlooked value in 109 and opportunities beyond head and neck cancer, with a $325 price target. The next proof points are longer follow-up, expansion results and Genmab’s numerical HPV breakdown.

$INBX Inhibrx's CEO, Mark Lappe, bought about $849,000 of the company's stock on Oct 14, 2026, through two family trusts. The Form 4 shows code P, a purchase, with the 10b5-1 plan box not ticked. It is the third buy filed since Sep 8: about $2.65M on Sep 8 and about $999,000 on Sep 25 and 28, about $4.49M in all. Source: SEC Form 4, filed Oct 14, 2026: https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/0001366074-26-000006-index.htm Information, not advice.

$INBX They go all the way here. Reminds me of PTGX at 15 where I hesitated and thought it will go lower.

$INBX $INBX is this a real biotech firm with legit future or is it just a flyby bio scam outfit ?? Anyone know ??? i dont

$INBX man does know a good value when he sees it .. unlime other ceos led by other ideologies or metrics this one clearly does what he says

$INBX CEO Mark Lappe bought another 10,040 shares on Wednesday at an average of $84.56, about 849,000 dollars worth (SEC Form 4). It is his fourth purchase since Sept 8: 25,000 shares at $105.82, then 5,500 at $99.16 and 4,500 at $100.76. Roughly 4.49 million dollars in across 45,040 shares, and the price he is paying keeps dropping. The stock closed Wednesday at $85.26, down about 19% over the past month.

$INBX marker goes up, this turd goes down. Market goes down this turd goes down more. Blah blah blah. Cheap value. Looks to be all nonsense. Value trap is what I see.

$INBX classic short play. Let it run up and then slam. Shorts appear to be in control. Price action is horrible. They need cash, dilution is coming. This is why I think the shorts are in control.

25 days out on $INBX and Seoul is where the next chapter lands imo Nov 20 oral at CTOS subgroup and updated PFS from the randomized Phase 2 ChonDRAgon study ozekibart in conventional chondrosarcoma, registrational setup Nov 19 brings the Ewing sarcoma poster too, same DR5 drug plus irinotecan and temozolomide

$INBX — CEO Lappe Mark bought $849K of stock on Oct 14. • 10,040 shares at $84.56. • Bought 46% below the 52-week high. • Stake up 1%.

$INBX Why so little cash? Unusual for quality bio. I would be interested, but this is strange. If someone can explain it to me: Thanks.